Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/64340
Type
ArticleCopyright
Restricted access
Embargo date
3100-12-31
Collections
Metadata
Show full item record
A SINGLE DOSE OF ANGIOTENSIN-(1-7) RESOLVES EOSINOPHILIC INFLAMMATION AND PROTECTS THE LUNGS FROM A SECONDARY INFLAMMATORY CHALLENGE.
Author
Magalhaes, Giselle Santos
Gregorio, Juliana Fabiana
Beltrami, Vinicius Amorim
Felix, Franciel Batista
Oliveira-Campos, Livia
Bonilha, Caio Santos
Righetti, Renato Fraga
Tibério, Iolanda de Fátima Lopes Calvo
Sousa, Frederico B De
Rezende, Barbara Maximino
Carvalho, Andréa Teixeira de
Santos, Robson As
Campagnole-Santos, Maria José
Rodrigues-Machado, Maria da Gloria
Teixeira, Mauro Martins
Pinho, Vanessa
Gregorio, Juliana Fabiana
Beltrami, Vinicius Amorim
Felix, Franciel Batista
Oliveira-Campos, Livia
Bonilha, Caio Santos
Righetti, Renato Fraga
Tibério, Iolanda de Fátima Lopes Calvo
Sousa, Frederico B De
Rezende, Barbara Maximino
Carvalho, Andréa Teixeira de
Santos, Robson As
Campagnole-Santos, Maria José
Rodrigues-Machado, Maria da Gloria
Teixeira, Mauro Martins
Pinho, Vanessa
Affilliation
René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Department of Physiology and Biophysics. National Institute of Science and Technology in Nanobiopharmaceutics. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Department of Morphology. Biological Sciences Institute. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Department of Morphology. Biological Sciences Institute. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Medical Sciences Faculty of Minas Gerais. Post-Graduate Program in Health Sciences. Belo Horizonte, MG, Brazil.
Center for Research in Inflammatory Diseases. University of São Paulo. São Paulo, SP, Brazil/Institute of Infection, Immunity and Inflammation. University of Glasgow. Glasgow, UK.
Faculty of Medicine. University of São Paulo. São Paulo, SP, Brazil/Rehabilitation Service. Hospital Sírio-Libanês. São Paulo, SP, Brazil.
Rehabilitation Service. Hospital Sírio-Libanês. São Paulo, SP, Brazil.
Laboratory of Polymeric and Supramolecular Systems. Institute of Physics and Chemistry. Federal University of Itajuba. Itajubá, MG, Brazil.
Department of Basic Nursing, School of Nursing, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Department of Physiology and Biophysics. National Institute of Science and Technology in Nanobiopharmaceutics. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Department of Physiology and Biophysics. National Institute of Science and Technology in Nanobiopharmaceutics. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Medical Sciences Faculty of Minas Gerais. Post-Graduate Program in Health Sciences. Belo Horizonte, MG, Brazil.
Department of Biochemistry and Immunology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Department of Morphology. Biological Sciences Institute. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil
Department of Physiology and Biophysics. National Institute of Science and Technology in Nanobiopharmaceutics. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Department of Morphology. Biological Sciences Institute. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Department of Morphology. Biological Sciences Institute. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Medical Sciences Faculty of Minas Gerais. Post-Graduate Program in Health Sciences. Belo Horizonte, MG, Brazil.
Center for Research in Inflammatory Diseases. University of São Paulo. São Paulo, SP, Brazil/Institute of Infection, Immunity and Inflammation. University of Glasgow. Glasgow, UK.
Faculty of Medicine. University of São Paulo. São Paulo, SP, Brazil/Rehabilitation Service. Hospital Sírio-Libanês. São Paulo, SP, Brazil.
Rehabilitation Service. Hospital Sírio-Libanês. São Paulo, SP, Brazil.
Laboratory of Polymeric and Supramolecular Systems. Institute of Physics and Chemistry. Federal University of Itajuba. Itajubá, MG, Brazil.
Department of Basic Nursing, School of Nursing, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brazil.
Department of Physiology and Biophysics. National Institute of Science and Technology in Nanobiopharmaceutics. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Department of Physiology and Biophysics. National Institute of Science and Technology in Nanobiopharmaceutics. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Medical Sciences Faculty of Minas Gerais. Post-Graduate Program in Health Sciences. Belo Horizonte, MG, Brazil.
Department of Biochemistry and Immunology. Institute of Biological Sciences. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil.
Department of Morphology. Biological Sciences Institute. Federal University of Minas Gerais. Belo Horizonte, MG, Brazil
Abstract
Objective: Angiotensin-(1-7) [Ang-(1-7)] is a pro-resolving mediator. It is not known whether the pro-resolving effects of Ang-(1-7) are sustained and protect the lung from a subsequent inflammatory challenge. This study sought to investigate the impact of treatment in face of a second allergic or lipopolysaccharide (LPS) challenge.
Methods: Mice, sensitized and challenged with ovalbumin (OVA), received a single Ang-(1-7) dose at the peak of eosinophilic inflammation, 24 h after the final OVA challenge. Subsequently, mice were euthanized at 48, 72, 96, and 120 h following the OVA challenge, and cellular infiltrate, inflammatory mediators, lung histopathology, and macrophage-mediated efferocytic activity were evaluated. The secondary inflammatory stimulus (OVA or LPS) was administered 120 h after the last OVA challenge, and subsequent inflammatory analyses were performed.
Results: Treatment with Ang-(1-7) resulted in elevated levels of IL-10, CD4+Foxp3+, Mres in the lungs and enhanced macrophage-mediated efferocytic capacity. Moreover, in allergic mice treated with Ang-(1-7) and then subjected to a secondary OVA challenge, inflammation was also reduced. Similarly, in mice exposed to LPS, Ang-(1-7) effectively prevented the lung inflammation.
Conclusion: A single dose of Ang-(1-7) resolves lung inflammation and protect the lung from a subsequent inflammatory challenge highlighting its potential therapeutic for individuals with asthma.
Share